Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.20 +1.5% SILVER 57.09 +2.2% COPPER 6.56 −1.6% OIL 97.94 +3.0% PALLADIUM 1131.50 +3.2% NTR 99.16 −0.3% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.180 −16.3% CLCH 1.06 −3.6% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.175 +2.9% EVI 0.500 +0.0% ADZ 0.120 −4.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.245 +0.0% BAU 0.180 −5.3% TECT 1.67 +0.6% GOLD 4170.20 +1.5% SILVER 57.09 +2.2% COPPER 6.56 −1.6% OIL 97.94 +3.0% PALLADIUM 1131.50 +3.2% NTR 99.16 −0.3% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.180 −16.3% CLCH 1.06 −3.6% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.175 +2.9% EVI 0.500 +0.0% ADZ 0.120 −4.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.245 +0.0% BAU 0.180 −5.3% TECT 1.67 +0.6%

Healthcare

Page 26
  1. Apr 30, 2026 · 08:30 · VVTM · Routine +

    Clinical Data Published in Peer-Reviewed Journal

    VVT Med Announces Positive Clinical Data for ScleroSafe(R) Published in Peer-Reviewed Indian Journal of Vascular and Endovascular Surgery

    01
  2. Apr 30, 2026 · 08:00 · APPT · Routine +

    UberDoc AI Partnership Validates Strategy But Liquidity and Revenue Visibility Remain Key Risks

    UberDoc Health Technologies Announces Strategic Partnership with XY.AI Labs to Expand Physician Network and Advance AI-Driven Practice Support

    02
  3. Apr 30, 2026 · 07:30 · APS · Neutral

    Hanmi Acquisition Closing Delayed to May as Korean Regulatory Review Continues

    Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical

    03
  4. Apr 30, 2026 · 07:15 · ASG · Routine +

    Aurora Spine Posts Record Revenue as Turnaround Strategy Takes Hold

    Aurora Spine Corporation Announces Record Fourth Quarter and FY25 Financial Results

    04
  5. Apr 30, 2026 · 07:00 · ARCH · Routine +

    Arch Biopartners Clinical Execution Continues Amidst Severe Capital Erosion and Liquidity Concerns

    Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI

    05
  6. Apr 30, 2026 · 07:00 · LSL · Neutral

    LSL Pharma Delivers Revenue Surge But Profitability Erosion Signals Costly Growth Phase

    LSL PHARMA GROUP REPORTS ITS FOURTH QUARTER AND YEAR-END 2025 RESULTS

    06
  7. Apr 30, 2026 · 07:00 · BLCO · Routine +

    Bausch + Lomb Pipeline Validation Follows Q1 Guidance Raise Amidst Margin Expansion

    Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting

    07
  8. Apr 30, 2026 · 04:03 · ASEP · Routine −

    ASEP Medical Raises Capital Amidst Leadership Churn and Dilution Concerns

    ASEP arranges $200,000 convertible debenture offering

    08
  9. Apr 29, 2026 · 20:51 · PCRX · Routine +

    PharmaCorp Rx Confirms M&A Execution but Stock Stalls Near Dilutive Offering Price

    PharmaCorp Announces Fourth Quarter and Fiscal Year 2025 Financial Results

    09
  10. Apr 29, 2026 · 18:01 · FNDX · Routine +

    Regulatory Clarity on Catheter Program Fails to Halt Steep Valuation Erosion Amidst Liquidity Strain

    FendX Engages Innovotech for Regulatory Pathway Assessment of Its Coated Foley Catheter Program

    10
  11. Apr 29, 2026 · 16:05 · DHT · Material +

    DRI Healthcare Trust Comments on Proposed Acquisition of KalVista Therapeutics, Inc.

    DRI Healthcare Trust Comments on Proposed Acquisition of KalVista Therapeutics, Inc.

    11
  12. Apr 29, 2026 · 16:05 · BHC · Routine +

    BHC Q1 Earnings Mask Pipeline Failure with Core Cash Flow Strength

    BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS

    12
  13. Apr 29, 2026 · 12:05 · NVRS · Routine −

    Noveris Health Sciences Inc.

    Noveris Health Sciences Provides Corporate Update, and Announces Agreement for Acquisition of Stem Cell Distribution Business

    13
  14. Apr 29, 2026 · 09:00 · METX · Routine +

    ME Therapeutics Advances mRNA Pipeline Amidst Price Consolidation at $2.50 Support Level

    ME Therapeutics Provides Scientific Update on In Vivo CAR and Therapeutic mRNA Programs

    14
← Newer Older →